Compare MasterCard Inc (MA) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Mesoblast Limited — how do they compare? MasterCard Inc trades at $546.79 (market cap $483.71B), while Mesoblast Limited trades at $16.08 (market cap $2.17B). The key difference: MasterCard Inc is far larger — about 222.9× Mesoblast Limited's market cap, and MasterCard Inc pays a 0.64% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MA | MESO | |
|---|---|---|
Market Cap | $483.71B | $2.17B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $598.96 | $20.96 |
52-Week Low | $471.55 | $12.88 |
Enterprise Value | $494.45B | $2.17B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $543.6, down 1.44% on the day, with strong technical support near $540 and bullish moving average signals. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding expectations of $4.41. Revenue grew to $32.79B in 2025, and net income margin remains high at 45.88%. Analysts maintain a strong buy consensus with a $634.27 price target, reflecting 16.7% upside potential.
Outlook remains positive driven by payment volume growth and AI initiatives, but risks include competitive disruption from stablecoins and high valuation multiples. Institutional ownership trends show continued accumulation, supporting bullish sentiment. The stock's current price is within 5% of recent highs, indicating potential for consolidation before further gains.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
